{"entity":{"id":"nct04417530","kind":"trial","name":"Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma","aka":[],"tldr":"A phase 2 trial of Belzupacap sarotalocan run by Aura Biosciences, completed.","summary":"Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma is a phase 2 interventional study registered as NCT04417530 by Aura Biosciences, with 22 participants enrolled, started 2020-08-05. Conditions recorded: Uveal Melanoma, Ocular Melanoma and Choroidal Melanoma. Interventions recorded: AU-011, Suprachoroidal Microinjector and PDT Laser.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT04417530","url":"https://clinicaltrials.gov/study/NCT04417530"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["uveal-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["belzupacap-sarotalocan"],"companies":["aura-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04417530","phase":"2","setting":"A Phase 2 Open-label, Ascending Single and Repeat Dose Escalation Trial of Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma","sponsor":"Aura Biosciences","enrolled":22,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04417530/","neighbours":{"cancer":[{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"drug":[{"id":"belzupacap-sarotalocan","kind":"drug","name":"Belzupacap sarotalocan","route":"/drugs/belzupacap-sarotalocan/"}],"company":[{"id":"aura-biosciences","kind":"company","name":"Aura Biosciences","route":"/companies/aura-biosciences/"}]}}